- Home
- BIIB vs BIP Comparison
BIIB vs BIP Comparison
Compare BIIB & BIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- BIP
- Stock Information
- Founded
- BIIB 1978
- BIP 2007
- Country
- BIIB United States
- BIP Bermuda
- Employees
- BIIB N/A
- BIP N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- BIP Marine Transportation
- Sector
- BIIB Health Care
- BIP Consumer Discretionary
- Exchange
- BIIB Nasdaq
- BIP Nasdaq
- Market Cap
- BIIB 18.8B
- BIP 15.7B
- IPO Year
- BIIB 1991
- BIP 2008
- Fundamental
- Price
- BIIB $124.99
- BIP $32.37
- Analyst Decision
- BIIB Buy
- BIP Strong Buy
- Analyst Count
- BIIB 27
- BIP 4
- Target Price
- BIIB $188.17
- BIP $44.50
- AVG Volume (30 Days)
- BIIB 1.2M
- BIP 418.0K
- Earning Date
- BIIB 07-31-2025
- BIP 07-31-2025
- Dividend Yield
- BIIB N/A
- BIP 5.32%
- EPS Growth
- BIIB 26.39
- BIP N/A
- EPS
- BIIB 10.12
- BIP 0.01
- Revenue
- BIIB $9,816,400,000.00
- BIP $21,244,000,000.00
- Revenue This Year
- BIIB N/A
- BIP N/A
- Revenue Next Year
- BIIB N/A
- BIP N/A
- P/E Ratio
- BIIB $12.35
- BIP $3,025.96
- Revenue Growth
- BIIB 1.59
- BIP 12.40
- 52 Week Low
- BIIB $110.04
- BIP $25.72
- 52 Week High
- BIIB $236.48
- BIP $36.50
- Technical
- Relative Strength Index (RSI)
- BIIB 41.14
- BIP 41.68
- Support Level
- BIIB $132.37
- BIP $32.09
- Resistance Level
- BIIB $137.84
- BIP $32.65
- Average True Range (ATR)
- BIIB 4.16
- BIP 0.54
- MACD
- BIIB -0.68
- BIP -0.15
- Stochastic Oscillator
- BIIB 7.82
- BIP 13.82
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About BIP Brookfield Infrastructure Partners LP
Brookfield Infrastructure Partners LP is a Bermuda exempted limited partnership that owns and operates quality, long-life assets that generate stable cash flows, by virtue of barriers to entry or other characteristics that tend to appreciate in value over time. It focuses on acquiring infrastructure assets that have low maintenance capital costs and high barriers to entry. The company's segments consist of Utilities, Transport, Midstream, and Data. Geographically, it generates maximum revenue from USA and also has a presence in Australia, Colombia, United Kingdom, Brazil, United States of America, Chile, Peru, and other countries.